355 related articles for article (PubMed ID: 32541216)
1. Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients.
Zhang H; Li R; Cao Y; Gu Y; Lin C; Liu X; Lv K; He X; Fang H; Jin K; Fei Y; Chen Y; Wang J; Liu H; Li H; Zhang H; He H; Zhang W
Ann Surg; 2022 Apr; 275(4):e626-e635. PubMed ID: 32541216
[TBL] [Abstract][Full Text] [Related]
2. Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.
Liu X; Cao Y; Li R; Gu Y; Chen Y; Qi Y; Lv K; Wang J; Yu K; Lin C; Liu H; Zhang H; He H; Chen L; Zhang P; Shen Z; Qin J; Sun Y; Li H; Huang H; Zhang W; Xu J
Eur J Cancer; 2020 Mar; 128():27-37. PubMed ID: 32109848
[TBL] [Abstract][Full Text] [Related]
3. Latency-associated Peptide Identifies Immunoevasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness.
Cao Y; He H; Li R; Liu X; Chen Y; Qi Y; Yu K; Wang J; Lin C; Liu H; Zhang H; Li H; Chen L; Zhang P; Shen Z; Huang H; Sun Y; Zhang W; Qin J; Xu J
Ann Surg; 2022 Jan; 275(1):e163-e173. PubMed ID: 32511132
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer.
Xu Y; Zeng H; Jin K; Liu Z; Zhu Y; Xu L; Wang Z; Chang Y; Xu J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338085
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response.
Qi Y; Chang Y; Wang Z; Chen L; Kong Y; Zhang P; Liu Z; Zhou Q; Chen Y; Wang J; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Y; Xu J; Zhang W
Cancer Immunol Immunother; 2019 Dec; 68(12):2067-2080. PubMed ID: 31720813
[TBL] [Abstract][Full Text] [Related]
6. Poor clinical outcomes and immunoevasive contexture in SIRPα
Xu Z; Zeng H; Liu Z; Jin K; Chang Y; Wang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Mar; 40(3):109.e11-109.e20. PubMed ID: 34600802
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral Foxp3
Fei Y; Cao Y; Gu Y; Fang H; Chen Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2022 Jan; 71(1):1-11. PubMed ID: 33978826
[TBL] [Abstract][Full Text] [Related]
8. Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients.
Jin K; Cao Y; Gu Y; Fang H; Fei Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Xu J
Oncoimmunology; 2021 Apr; 10(1):1915560. PubMed ID: 33996266
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral CD103
Gu Y; Chen Y; Jin K; Cao Y; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Qin J; Li R; Zhang H; Zhang W
Oncoimmunology; 2020 Nov; 9(1):1844402. PubMed ID: 33312758
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating podoplanin
Liu X; Cao Y; Lv K; Gu Y; Jin K; He X; Fang H; Fei Y; Shi M; Lin C; Liu H; Li H; He H; Xu J; Li R; Zhang H
Oncoimmunology; 2020 Nov; 9(1):1845038. PubMed ID: 33235820
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
12. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
Xu C; Fang H; Gu Y; Yu K; Wang J; Lin C; Zhang H; Li H; He H; Liu H; Li R
Cancer Sci; 2022 Dec; 113(12):4070-4081. PubMed ID: 35997524
[TBL] [Abstract][Full Text] [Related]
13. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
14. Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer.
He X; Gu Y; Cao Y; Hu B; Fang H; Fei Y; Lv K; Liu X; Wang J; Lin C; Liu H; Zhang H; Li H; Li R; He H; Xu J
Eur J Cancer; 2021 Nov; 157():114-123. PubMed ID: 34508993
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients.
He X; Cao Y; Gu Y; Fang H; Wang J; Liu X; Lv K; Yu K; Fei Y; Lin C; Liu H; Zhang H; Li H; Xu J; Li R; He H
Ann Surg Oncol; 2021 Oct; 28(11):6439-6450. PubMed ID: 33738713
[TBL] [Abstract][Full Text] [Related]
16. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte-activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epstein-Barr virus-positive and MLH1-defective gastric cancer patients.
Lv K; Li R; Cao Y; Gu Y; Liu X; He X; Jin K; Fang H; Fei Y; Shi M; Liu H; Li H; He H; Lin C; Zhang H; Xu J
Int J Cancer; 2021 Feb; 148(3):759-768. PubMed ID: 33105024
[TBL] [Abstract][Full Text] [Related]
18. Poor Prognosis and Therapeutic Responses in LILRB1-Expressing M2 Macrophages-Enriched Gastric Cancer Patients.
Zhang Y; Wang H; Xu X; Liu H; Hao T; Yin S; Zhang C; He Y
Front Oncol; 2021; 11():668707. PubMed ID: 34485116
[TBL] [Abstract][Full Text] [Related]
19. Siglec9 + tumor-associated macrophages predict prognosis and therapeutic vulnerability in patients with colon cancer.
Chang J; Feng Q; Mao Y; Zhang Z; Xu Y; Chen Y; Zheng P; Lin S; Shen F; Zhang Z; Zhang Z; He G; Xu J; Wei Y
Int Immunopharmacol; 2024 Mar; 130():111771. PubMed ID: 38430807
[TBL] [Abstract][Full Text] [Related]
20. Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer.
Zhou Q; Zhang H; Wang Z; Zeng H; Liu Z; Huang Q; Lin Z; Qu Y; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Dai B; Guo J; Zhu Y; Xu L; Xu J
Int J Cancer; 2020 Dec; 147(12):3539-3549. PubMed ID: 32734613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
